Emerging Lung Cancer Treatments with ADC
Dr. Feinstein presented on emerging lung cancer treatments at the 2024 OneOncology annual conference, highlighting an intriguing new approach involving antibody drug conjugates.
An antibody drug conjugate (ADC) is a therapeutic agent that merges a monoclonal antibody with a drug specifically for cancer treatment. The antibody attaches to a specific protein (or receptor) on the cancer cell's surface, allowing it to enter and ultimately destroy the cell. ADCs are typically employed when other treatments have been unsuccessful or when cancer has progressed.
Years of collaboration between academia and industry have resulted in the successful creation of various ADC therapies, benefiting tens of thousands of cancer patients. The introduction of 14 ADC drugs, alongside the promising clinical outcomes of additional ADC candidates, is generating increased interest in this critical yet complex field.
